Advisory Committee

INFINIUM SPIRITS ANNOUNCES NEW PRESIDENT - JAN THARP

Retrieved on: 
Tuesday, January 17, 2023
National Advisory Committee for Women, Tharp, Executive, Advisory Committee, School, Information Holdings Inc., European Leadership Network, Michigan State University Federal Credit Union, Growth, CPG, SAN, Bumble Bee Foods, Food, Management

SAN DIEGO, Jan. 17, 2023 /PRNewswire/ --Infinium Spirits Inc., a global premium spirits company based in San Diego, California; announces the appointment of Jan Tharp as President.

Key Points: 
  • SAN DIEGO, Jan. 17, 2023 /PRNewswire/ --Infinium Spirits Inc., a global premium spirits company based in San Diego, California; announces the appointment of Jan Tharp as President.
  • Prior to being named President and CEO, she held the role of Executive Vice President and Chief Operating Officer.
  • "I am thrilled Jan is joining Infinium Spirits as President.
  • "I am honored and privileged to lead the incredibly talented Infinium Spirits team as President," said Tharp.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of Investors

Retrieved on: 
Friday, January 20, 2023
Class Action Lawsuit, Professional Services, Legal, News, Therapy, Advisory Committee, CNS, Regulation of tobacco by the U.S. Food and Drug Administration, FDA, Person, GPM, Neuroblastoma, Food, BLA, Patient, Investment, Pharmaceutical industry

Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB ) investors concerning the Company’s possible violations of the federal securities laws.

Key Points: 
  • Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB ) investors concerning the Company’s possible violations of the federal securities laws.
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On October 26, 2022, the FDA released its briefing document in advance of its Advisory Committee meeting to discuss the omburtamab BLA.
  • Whistleblower Notice: Persons with non-public information regarding Y-mAbs should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of Investors

Retrieved on: 
Thursday, January 19, 2023
Class Action Lawsuit, Professional Services, Legal, News, Therapy, Advisory Committee, CNS, Regulation of tobacco by the U.S. Food and Drug Administration, FDA, Telephone, Neuroblastoma, Food, BLA, Patient, Suite, Pharmaceutical industry

Law Offices of Howard G. Smith announces an investigation on behalf of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB ) investors concerning the Company’s possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith announces an investigation on behalf of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB ) investors concerning the Company’s possible violations of federal securities laws.
  • On October 26, 2022, the FDA released its briefing document in advance of its Advisory Committee meeting to discuss the omburtamab BLA.
  • On this news, Y-mAbs’s stock price fell $4.16, or 27.4%, to close at $11.01 per share on October 26, 2022, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

The Law Offices of Frank R. Cruz Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of Investors

Retrieved on: 
Thursday, January 19, 2023
Class Action Lawsuit, Professional Services, Legal, News, Therapy, Advisory Committee, CNS, Law, Regulation of tobacco by the U.S. Food and Drug Administration, FDA, Neuroblastoma, Food, BLA, Patient, Suite, Pharmaceutical industry

The Law Offices of Frank R. Cruz announces an investigation of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB ) on behalf of investors concerning the Company’s possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz announces an investigation of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB ) on behalf of investors concerning the Company’s possible violations of federal securities laws.
  • On October 26, 2022, the FDA released its briefing document in advance of its Advisory Committee meeting to discuss the omburtamab BLA.
  • On this news, Y-mAbs’s stock price fell $4.16, or 27.4%, to close at $11.01 per share on October 26, 2022, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Y-MABS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Y-mAbs Therapeutics, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, January 20, 2023
Class Action Lawsuit, Professional Services, Legal, RTF, Database, Spinal cord, Radiation, Overalls, Memorial Sloan Kettering Cancer Center, Brain, OS, Element, CSF, Person, Therapy, Advisory Committee, Aerospace, Form 10-K, CNS, District court, Safety, FDA, LM, Biologics license application, Placebo, Telephone, Jeanne Eagels, Neuroblastoma, Marketing, Central nervous system, Survival, BLA, Patient, Observation, Court, ORR, NB, MRI, Letter, Disclosure, P.C, CFR, Medical imaging, Pharmaceutical industry, Petroleum jelly, Medicine, Medical device, Dietary supplement

Investors have until March 20, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until March 20, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • According to Y-mAbs’s 2021 Form 10-K (at 27), there are approximately 700 children diagnosed with neuroblastoma (NB) in the United States each year.
  • Of those, approximately 50-60% are high-risk, and of those at high-risk who relapse, Y-mAbs believes approximately 20% will suffer from leptomeningeal (central nervous system) metastases from neuroblastoma.
  • The efficacy population in Study 03-133 consisted of a subset of 94 patients ages 0.9 to 13 years.

INVESTOR NOTICE: Y-mAbs Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Y-mAbs Class Action Lawsuit - YMAB

Retrieved on: 
Thursday, January 19, 2023
Class Action Lawsuit, Professional Services, Legal, News, Therapy, Advisory Committee, Aerospace, FDA, Neuroblastoma, Marketing, Registration statement, Central nervous system, Food, Patient, Cancer, CASE, Tobacco, Pharmaceutical industry

), the Y-mAbs class action lawsuit charges Y-mAbs and certain of its top executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the Y-mAbs class action lawsuit charges Y-mAbs and certain of its top executives with violations of the Securities Exchange Act of 1934.
  • A lead plaintiff acts on behalf of all other class members in directing the Y-mAbs class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the Y-mAbs class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Y-mAbs class action lawsuit.

Report Demonstrates that Pharmacist-Administered Vaccinations Have Increased Since the Onset of the Covid-19 Pandemic

Retrieved on: 
Wednesday, January 18, 2023
Technology, Insurance, Professional Services, Public Policy, Government, Health Insurance, Software, State, Local, Pharmaceutical, Health, Data Management, Pharmacist, Congress, HPV, Social media, Overalls, COVID, Publication, Advisory Committee, COVID-19, MS, Pharmacy, Doctor of Pharmacy, FDA, IQVIA, Vaccination, Pharmacy technician, Immunization, Vaccine, Conditional sentence, Health policy, Adolescence, Food, Economics, Legislation, Health equity, Research, Shingles, Public Readiness and Emergency Preparedness Act, Influenza, ACIP, Policy, Advisory Committee on Immunization Practices, Social, Pharmaceutical industry

The PREP Act will lapse in 2024 in 25 States where this authority has not yet been made permanent by new state laws.

Key Points: 
  • The PREP Act will lapse in 2024 in 25 States where this authority has not yet been made permanent by new state laws.
  • For example, while HPV vaccines are generally used in adolescent populations, 20 percent of all HPV vaccine claims are for adults.
  • Specifically, Hispanic and Asian populations receive a larger share of vaccines at pharmacies compared to other race/ethnicity categories.
  • Our researchers also address these important topics through opinion editorials, speaking engagements, and our world-class podcast series – Healthcare Matters.

GARP Celebrates 25th Anniversary of Flagship Financial Risk Manager (FRM®) Certification

Retrieved on: 
Tuesday, January 17, 2023
Professional Services, Insurance, Finance, Asset Management, Consulting, Banking, Certification, Global Association of Risk Professionals, FRM, Advisory Committee, COVID-19, Curriculum, Machine learning, CBT, Test (assessment), Risk management, Traction, GARP, Medicine

The Global Association of Risk Professionals (GARP) recently celebrated the 25th anniversary of its flagship Financial Risk Manager (FRM®) program, the leading certification for risk managers around the world.

Key Points: 
  • The Global Association of Risk Professionals (GARP) recently celebrated the 25th anniversary of its flagship Financial Risk Manager (FRM®) program, the leading certification for risk managers around the world.
  • GARP’s FRM Certification has been successfully earned by over 77,000 professionals to date, with many more scheduled to take their Exams in 2023.
  • "The FRM’s initial traction came primarily from word-of-mouth communication, a trend that continues today,” said Richard Apostolik, president and CEO of GARP.
  • These changes prioritize candidate flexibility and convenience, reflecting GARP’s tireless dedication to ensuring its flagship certification stays agile and modern.

Deep Borehole Demonstration Center Announced with Launch Executive Director Ted Garrish

Retrieved on: 
Friday, January 13, 2023
Carbon, Waste management, R, Waste, University, Nuclear Waste Technical Review Board, Advisory Committee, U.S. Department of Defense Strategy for Operating in Cyberspace, Energy Technology Engineering Center, Government, Safety, Environment, Symposia, Army Heritage Center Foundation, U.S. Department of Energy, Office of Inspector General, Jitka, Assistant, Earth science, Power plant engineering, Private sector, Renewable energy, Lithium, Mining, Southern Company

BERKELEY, Calif., Jan. 12, 2023 /PRNewswire-PRWeb/ -- A new Deep Borehole Demonstration Center will be publicly launched Feb. 27 at the Waste Management Symposia in Phoenix, Ariz. It was founded as a new nonprofit organization and is open to participation from governments, utilities, nuclear operators and research organizations interested in studying nuclear waste disposal technologies for worldwide deployment.

Key Points: 
  • BERKELEY, Calif., Jan. 12, 2023 /PRNewswire-PRWeb/ -- A new Deep Borehole Demonstration Center will be publicly launched Feb. 27 at the Waste Management Symposia in Phoenix, Ariz.
  • The Board has appointed Ted Garrish, former Assistant Secretary for International Affairs at the U.S. Department of Energy, to serve as Launch Executive Director.
  • The Deep Borehole Demonstration Center will allow multinational and cross-organizational collaborations to begin the work of characterizing the entire system.
  • "On behalf of the Czech partners I am representing, we are looking forward to engaging in the Deep Borehole Demonstration Center work."

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Veru Inc. - VERU

Retrieved on: 
Monday, January 9, 2023
Defense Department Advisory Committee on Women in the Services, News, Acute respiratory distress syndrome, Advisory Committee, COVID-19, Food, Patient, Pharmaceutical industry

NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (“Veru” or the “Company”) (NASDAQ: VERU).

Key Points: 
  • NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (“Veru” or the “Company”) (NASDAQ: VERU).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Veru and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.